CATB Catabasis Pharmaceuticals, Inc.

4.16
-0.34  -7.56%
Previous Close 4.50
Open 4.50
Price To book 2.28
Market Cap 77.59M
Shares 18,652,000
Volume 257,986
Short Ratio 1.60
Av. Daily Volume 186,466

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 161988011
  2. 424B5 - Prospectus [Rule 424(b)(5)] 161987956
  3. 8-K - Current report 161978065
  4. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 161917977
  5. 8-K - Current report 161917200

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a did not meet primary endpoint - June 2016
CAT-2054
Hypercholesterolemia
Phase 2 top-line data due first half of 1Q 2017.
CAT-1004
Duchenne muscular dystrophy (DMD)

Latest News

  1. Catabasis Muscular Dystrophy Drug Posts Early Win
  2. Thursday’s Top Biopharma Movers
  3. Catabasis Pharma surges 17% on positive early-stage clinical trial results for DMD drug
  4. Catabasis Pharmaceuticals Phase 1 Data on Edasalonexent (CAT-1004), a Potential Disease-Modifying Therapy Being Developed for Duchenne Muscular Dystrophy, Published in the Journal of Clinical Pharmacology
  5. Mead Johnson (MJN) Q4 Earnings: Disappointment in Store?
  6. Will Catabasis Pharmaceuticals (CATB) Continue to Surge Higher?
  7. Catabasis Pharmaceuticals Research on CAT-5571, a Novel Activator of Autophagy and Potential Oral Treatment for Cystic Fibrosis, Published in Journal of Medicinal Chemistry
  8. Catabasis Pharmaceuticals Research on CAT-5571, a Novel Activator of Autophagy and Potential Oral Treatment for Cystic Fibrosis, Published in Journal of Medicinal Chemistry
  9. Positive Preclinical Research on the Edasalonexent (CAT-1004) Program, a Potential Disease-Modifying Therapy for Duchenne Muscular Dystrophy, Published in JCI Insight
  10. Positive Preclinical Research on the Edasalonexent (CAT-1004) Program, a Potential Disease-Modifying Therapy for Duchenne Muscular Dystrophy, Published in JCI Insight
  11. New Strong Buy Stocks for December 30th
  12. Coverage initiated on Catabasis Pharmaceuticals by H.C. Wainwright
  13. How Five Star Quality Care, Inc. (FVE) Stacks Up Against Its Peers
  14. Catabasis Pharmaceuticals, Inc. :CATB-US: Earnings Analysis: Q3, 2016 By the Numbers : December 6, 2016
  15. CATABASIS PHARMACEUTICALS INC Financials
  16. Catabasis Pharmaceuticals Provides Edasalonexent and Rare Disease Pipeline Updates at Investor Day
  17. Catabasis Pharmaceuticals, Inc. (Nasdaq: CATB) to Ring The Nasdaq Stock Market Closing Bell
  18. Edited Transcript of CATB earnings conference call or presentation 10-Nov-16 9:30pm GMT
  19. Catabasis Pharmaceuticals Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights
  20. Catabasis Pharmaceuticals Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 161988011
  2. 424B5 - Prospectus [Rule 424(b)(5)] 161987956
  3. 8-K - Current report 161978065
  4. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 161917977
  5. 8-K - Current report 161917200
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 161911085
  7. 8-K - Current report 161900117
  8. 424B5 - Prospectus [Rule 424(b)(5)] 161900025
  9. 424B5 - Prospectus [Rule 424(b)(5)] 161898559
  10. 8-K - Current report 161824656